ENTYVIO (Vedolizumab) Drug Insight and Market Forecast – 2032

ENTYVIO (Vedolizumab) Drug Insight and Market Forecast – 2032

“ENTYVIO (Vedolizumab), Drug Insight and Market Forecast – 2032” report provides comprehensive insights about ENTYVIO (Vedolizumab) for Crohn’s disease (CD) in the 7MM. A detailed picture of the ENTYVIO (Vedolizumab) for Crohn’s disease (CD) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the ENTYVIO (Vedolizumab) for Crohn’s disease (CD). The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ENTYVIO (Vedolizumab) market forecast, analysis for Crohn’s disease (CD) in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Crohn’s disease (CD).

Drug Summary

ENTYVIO (Vedolizumab) is a gut-selective biologic developed by Takeda Pharmaceutical and marketed under the trade name ENTYVIO. It is approved in the US for the treatment of adult patients with moderately to severely active Ulcerative Colitis (UC) and Crohn’s disease (CD), who have had an inadequate response to, lost response to, or were intolerant to either conventional therapy or a Tumor Necrosis Factor-alpha (TNFα)-antagonist. It is a humanized monoclonal antibody designed to specifically antagonize the alpha 4 beta 7 integrin, inhibiting the binding of alpha 4 beta 7 integrin to intestinal Mucosal Addressin Cell Adhesion Molecule 1 (MAdCAM-1), but not Vascular Cell Adhesion Molecule 1 (VCAM-1).

MAdCAM-1 is preferentially expressed in blood vessels and lymph nodes of the gastrointestinal tract. The alpha 4 beta 7 integrin is expressed on a subset of circulating white blood cells. These cells have been shown to play a role in mediating the inflammatory process in UC and CD. By inhibiting alpha 4 beta 7 integrin, vedolizumab may limit the ability of certain white blood cells to infiltrate gut tissues.

Dosage

The recommended dosage of ENTYVIO in adults with UC is 300 mg administered by intravenous infusion at 0, 2, and 6 weeks and then every 8 weeks after that. It is recommended to discontinue therapy in patients who show no evidence of therapeutic benefit by Week 14.

Mechanism of Action

Vedolizumab is a humanized monoclonal antibody that specifically binds to the α4β7 integrin and blocks the interaction of α4β7 integrin with Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) and inhibits the migration of memory T-lymphocytes across the endothelium into inflamed gastrointestinal parenchymal tissue. Vedolizumab does not bind to or inhibit the function of the α4β1 and αEβ7 integrins and does not antagonize the interaction of α4 integrins with Vascular Cell Adhesion Molecule-1 (VCAM-1).

The α4β7 integrin is expressed on the surface of a discrete subset of memory T-lymphocytes that preferentially migrate into the gastrointestinal tract. MAdCAM-1 is mainly expressed on gut endothelial cells and plays a critical role in the homing of T-lymphocytes to gut lymph tissue. The interaction of the α4β7 integrin with MAdCAM-1 has been implicated as an important contributor to the chronic inflammation that is a hallmark of ulcerative colitis and Crohn’s disease.

Scope of the Report

The report provides insights into:

A comprehensive product overview including the ENTYVIO (Vedolizumab) description, mechanism of action, dosage and administration, research and development activities in Crohn’s disease (CD).

Elaborated details on ENTYVIO (Vedolizumab) regulatory milestones and other development activities have been provided in this report.

The report also highlights the ENTYVIO (Vedolizumab) research and development activity in Crohn’s disease (CD) in detail across the United States, Europe and Japan.

The report also covers the patents information with expiry timeline around ENTYVIO (Vedolizumab).

The report contains forecasted sales of ENTYVIO (Vedolizumab) for Crohn’s disease (CD) till 2032.

Comprehensive coverage of the late-stage emerging therapies for Crohn’s disease (CD).

The report also features the SWOT analysis with analyst views for ENTYVIO (Vedolizumab) in Crohn’s disease (CD).

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ENTYVIO (Vedolizumab) Analytical Perspective by DelveInsight

In-depth ENTYVIO (Vedolizumab) Market Assessment

This report provides a detailed market assessment of ENTYVIO (Vedolizumab) in Crohn’s disease (CD) in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

ENTYVIO (Vedolizumab) Clinical Assessment

The report provides the clinical trials information of ENTYVIO (Vedolizumab) in Crohn’s disease (CD) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

In the coming years, the market scenario for Crohn’s disease (CD) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ENTYVIO (Vedolizumab) dominance.

Other emerging products for Crohn’s disease (CD) are expected to give tough market competition to ENTYVIO (Vedolizumab) and launch of late-stage emerging therapies in the near future will significantly impact the market.

A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ENTYVIO (Vedolizumab) in Crohn’s disease (CD).

Our in-depth analysis of the forecasted sales data of ENTYVIO (Vedolizumab) from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ENTYVIO (Vedolizumab) in Crohn’s disease (CD).

Key Questions

What is the product type, route of administration and mechanism of action of ENTYVIO (Vedolizumab)?

What is the clinical trial status of the study related to ENTYVIO (Vedolizumab) in Crohn’s disease (CD) and study completion date?

What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ENTYVIO (Vedolizumab) development?

What are the key designations that have been granted to ENTYVIO (Vedolizumab) for Crohn’s disease (CD)?

What is the forecasted market scenario of ENTYVIO (Vedolizumab) for Crohn’s disease (CD)?

What are the forecasted sales of ENTYVIO (Vedolizumab) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?

What are the other emerging products available in Crohn’s disease (CD) and how are they giving competition to ENTYVIO (Vedolizumab) for Crohn’s disease (CD)?

Which are the late-stage emerging therapies under development for the treatment of Crohn’s disease (CD)?